Supreme Court Leaves Room for Big Business in Synthetic DNA

The Supreme Court's gene patenting decision left plenty of room for profitable business in synthetic DNA, Wall Street is indicating. Myriad Genetics, the genetics research company involved by the case decided Thursday, is up more than 8% in mid-day trading:

While there's no guarantee Myriad will end the day quite so high, this is a sign investors are positive about Myriad's future. Rightfully so: While the Supreme Court found organic DNA can't be patented, it conceded that synthetically engineered DNA can be protected by a patent